Poland· PL-100400759
Fasenra
A benralizumab product containing benralizumabum, registered in Poland by AstraZeneca AB. The same ATC class is registered in 16 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Benralizumab is registered in 16 of 19 countries.
Countries holding a registration under ATC R03DX10 (benralizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Benralizumab · ATC R03DX10
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Benralizumabum
- Manufacturer
- AstraZeneca AB
- Country
- Poland (PL)
- ATC code
- R03DX10
- ATC class
- Benralizumab
- Defined daily dose
- 0.54 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05000456031516
- gtin05000456059213
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Benralizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandFasenra Pen
- FinlandFasenraAstraZeneca AB
- United StatesFASENRAAstraZeneca Pharmaceuticals LP
- Japanベンラリズマブ（遺伝子組換え）アストラゼネカ
- NorwayFasenra2care4 ApS
- SpainFASENRA 30 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAAstrazeneca Ab
- FranceFASENRA 30 mg, solution injectable en seringue préremplieASTRAZENECA AB
- United KingdomFasenra 30mg/1ml solution for injection pre-filled pensAstraZeneca UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Fasenra
- Liechtenstein · Fasenra
- Norway · Fasenra
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/166c4da6-4de4-4222-85a4-abfc46de8d80 GET /v1/drugs/166c4da6-4de4-4222-85a4-abfc46de8d80?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "30 mg/ml",
"packaging": "05000456031516 ¦ Rpz ¦ EU/1/17/1252/001 ¦ 126577\n1 amp.-strzyk. 1 ml\n05000456059213 ¦ Rpz ¦ EU/1/17/1252/002 ¦ 135786\n1 wstrzykiwacz 1 ml",
"substance": "Benralizumabum 30 mg/ml",
"common_name": "Benralizumabum",
"pl_product_id": "100400759",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about benralizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.